Go Back This article was viewed 80 times

Letter to Editor


Putting viruses to work in CAR therapies

Divyesh G. Mehta
Department of Medicine, University of Arizona College of Medicine, Division Chair, Hematology Oncology, Maricopa Integrated Health Services, Phoenix, AZ, USA
Corresponding Author:

Divyesh G. Mehta

Department of Medicine, University of Arizona College of Medicine, Division Chair, Hematology Oncology, Maricopa Integrated Health Services, Phoenix, AZ, USA
E-mail: divyeshm@gmail.com

Corresponding Author:

Divyesh G. Mehta

Department of Medicine, University of Arizona College of Medicine, Division Chair, Hematology Oncology, Maricopa Integrated Health Services, Phoenix, AZ, USA
E-mail: divyeshm@gmail.com

DOI:10.18203/issn.2456-3994.IntJMolImmunoOncol20170057

ABSTRACT


The difference between the patient who gets cured after surgery, chemotherapy and event targeted therapies and who relapses with a small quantum of intrepid cancer cells is whether the Dendritic cell T cell complex could find and eliminate residual minimal tumour load. A very significant chapter in these battles has opened up with the Chimeric Antigen Receptor (CAR) Therapy. Many B cell Neoplasms express CD19. CARs can be engineered into viruses and expressed by T cells. CAR T cells with anti CD19 faculties can be transferred to the patient. This novel therapy shows many promises and raises new questions.
Keywords: mmunotherapy, Chimeric, T cell, Viruses, Dendritic cell

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.